Characterization of Macroprolactinemia

Learn more about:
Related Clinical Trial
Administration of Kisspeptin to Subjects With Reproductive Disorders The Luveris In Vitro Fertilization Trial A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Pituitary Function and Spontaneous Intracranial Hypotension Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility Aripiprazole and Prolactin Study Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Characterization of Macroprolactinemia Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Endometriosis Patients Undergoing Quinagolide Treatment Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire Hyperprolactinemia and Adrenal Steroidogenesis Administration of Kisspeptin in Patients With Hyperprolactinemia Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Brief Title

Characterization of Macroprolactinemia


Brief Summary

      The purpose of this study is to clarify the nature of macroprolactin which has recently been
      highlighted because of the high prevalence and a diagnostic pitfall of hyperprolactinemia.
      The results of this study are beneficial for the patients to whom unnecessary medications and
      unnecessary radiological examinations have been performed.

      We used the remained serum samples taken for routine prolactin determination during the past
      several years. Since the blood was basically taken to examine the causes of
      hyperprolactinemia and only remained serum samples were used for this study, the Ethics
      Committee of Kobe City General Hospital judged that it was not required to obtain approval
      number.
    



Study Type

Observational




Condition

Hyperprolactinemia



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information




Start Date

January 2005

Completion Date

December 2006


Eligibility Criteria

        Inclusion Criteria:

          -  Clinical diagnosis of hyperprolactinemia
      

Gender

All

Ages

N/A - N/A


Contacts

Naoki Hattori, M.D., Ph.D., , 

Location Countries

Japan

Location Countries

Japan

Administrative Informations


NCT ID

NCT00436111

Organization ID

KK-2007-1



Study Sponsor

Kansai Medical University


Study Sponsor

Naoki Hattori, M.D., Ph.D., Study Chair, Department of Pharmacology, Kansai Medical University


Verification Date

February 2007